The content on this site is intended for healthcare professionals only
Dr Scarfo speaks with ecancer at EHA 23 about a multicentre international study which finds 50% of CLL patients who have received Brutons tyrosine kinase inhibitor ibrutinib in the course of their CLL treatment who relapse harbour mutations in BTK and associated PLCG2 genes.
She outlines the recruitment procedure and patient cohort, and implications of these findings for screening and treatment guidance.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma
New classification for identifying HR myeloma based on cytogenetic abnormalities
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Advancing breast cancer treatment in Uganda by improving molecular testing
Somatic mutation profile of breast cancer in Uganda
